OncLive TV

Anna B. Halpern, MD, discusses symptom control, transfusion independence, and spleen volume findings with the JAK and ACVR1 inhibitor momelotinib vs the JAK inhibitor ruxolitinib and danazol in patients with myelofibrosis with anemia.

Harry P. Erba, MD, PhD, discusses the significance of the FDA approval of quizartinib in combination with chemotherapy in patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.

Adnan F. Danish, MD, discusses the use of SCINTIX radiation technology in metastatic bone and lung tumors.

Nikhil C. Munshi, MD, discusses the implications of the findings from the phase 1b/2 CARTITUDE-1 trial of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and the CAR T-cell therapy’s subsequent FDA approval for use in this patient population.

Rami Komrokji, MD, shares the potential clinical implications of data from the phase 3 COMMANDS trial of luspatercept in patients with very low– to intermediate-risk myelodysplastic syndromes who have not received prior treatment with an erythropoiesis-stimulating agents.

Matthew Galsky, MD, discusses how updated findings from the phase 3 CheckMate 274 study confirm the efficacy of adjuvant systemic immunotherapy in metastatic urothelial carcinoma.

John M. Burke, MD, discusses several ongoing or upcoming investigations of targeted therapy in mantle cell lymphoma.

Benjamin Miron, MD, discusses the methods utilized in a study of molecular alterations in patients with intraductal carcinoma of the prostate and the next steps for this research.

Nausheen Ahmed, MD, discusses the rationale for investigating real-world outcomes of patients with relapsed/refractory mantle cell lymphoma treated with brexucabtagene autoleucel.

Jayesh Desai, MBBS, FRACP, discusses the evolution of divarasib, highlighting the rationale for combining the KRAS G12C inhibitor with cetuximab in patients with advanced colorectal cancer harboring KRAS G12C mutations in a phase 1b study.

Senthil Damodaran, MD, PhD, discusses the rationale for the phase 3 ELAINE-3 trial in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.

Michelina Cairo, MD, discusses the adverse effect profiles of trastuzumab emtansine and trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer.

Sabina Signoretti, MD, discusses research into the development of novel spatial biomarkers in renal cell carcinoma utilizing tissue-based in situ analyses.

Raquibul Hannan, MD, PhD, discusses the advantages of stereotactic radiation in primary or locally advanced renal cell carcinoma.

Yasser Mohamed Ali Ged, MBBS, discusses the background of launching the phase 2 ORCHID trial evaluating olaparib monotherapy in patients with metastatic renal cell carcinoma harboring BAP1 or other DNA repair gene mutations.

Julien Taieb, MD, PhD, discusses the safety profile associated with trifluridine/tipiracil with bevacizumab in refractory metastatic colorectal cancer.

Benjamin H. Lowentritt, MD, FACS, discusses the background and rationale for conducting a real-world retrospective study of prostate-specific antigen responses generated from second-generation androgen receptor inhibitors in patients with metastatic castration-sensitive prostate cancer.

Tian Zhang, MD, MHS, discusses whether the use of RNA sequencing to identify biologic cluster assignment could improve first-line treatment selection in metastatic renal cell carcinoma.

Maxine Sun, PhD, MPH, discusses the association between clonal hematopoiesis and cardiovascular disease in patients with renal cell carcinoma

Jeffrey V. Matous, MD, discusses upcoming and ongoing clinical trials in multiple myeloma being conducted at the Colorado Blood Cancer Institute.

Alexey Danilov, MD, PhD, discusses lingering questions that remain across the treatment landscape of mantle cell lymphoma.

Adnan F. Danish, MD, discusses unmet needs in the treatment of patients with lung and bone cancers, and how unmet needs within this patient population are being addressed with the utilization of SCINTIX radiation technology.

Paolo Tarantino, MD, discusses the expansion and selection of effective treatment options for patients with hormone receptor-positive breast cancer who progressed on a CDK 4/6 inhibitor.

Luis E. Raez, MD, discusses how findings from the phase 2 NADIM II trial inform the neoadjuvant treatment paradigm in non–small cell lung cancer.

Rami Komrokji, MD, discusses the clinical implications of the phase 3 COMMANDS trial in patients with very low–, low-, or intermediate-risk myelodysplastic syndromes who have not received prior treatment with an erythropoiesis-stimulating agents.

Michael Basin, MD, discusses the design of a preclinical investigation into the pharmacological inhibition of the molecular chaperone Hsp70 and how it relates to belzutifan resistance in clear cell renal cell carcinoma.

Jeffrey V. Matous, MD, discusses the benefit derived from the phase 3 IKEMA trial in patients with relapsed/refractory multiple myeloma, highlighting the key factors to take into account when evaluating patients for relapsed/refractory disease within this treatment space.

Alexey Danilov, MD, PhD, discusses treatment developments for patients with mantle cell lymphoma who have progressed on BTK inhibitors.

Callie Coombs, MD, discusses treatment updates in patients with chronic lymphocytic leukemia.

Chung-Han Lee, MD, PhD, discusses the final results of the phase 2 cohort of a phase 1/2 trial evaluating lenvatinib plus pembrolizumab in patients with pretreated metastatic clear cell renal cell carcinoma.